Skip to main content
Top
Published in: Digestive Diseases and Sciences 2/2008

01-02-2008 | Original Paper

Prevalence of Macrocreatinkinase Type 1 in Patients with Inflammatory Bowel Disease

Authors: J. L. Perez-Calle, I. Marin-Jimenez, P. Lopez-Serrano, J. P. Gisbert, A. S. Pena, C. Fernandez-Rodriguez

Published in: Digestive Diseases and Sciences | Issue 2/2008

Login to get access

Abstract

Macro-creatine-kinases are isoenzymes of creatinine-kinases (CK). They have been classified in two types: type 1 (CK bound to an immunoglobulin) and type 2 (an oligomeric mitochondrial CK). CK type 1 has been found in patients with ulcerative colitis (UC) but not in Crohn’s disease (CD). However, there are no studies evaluating macro-creatinkinase prevalence in inflammatory bowel disease (IBD). We included 159 consecutive patients (72 UC, 85 CD; 2 indeterminate colitis). Creatin-kinase total activity and isoenzymes activities were determined. Twelve (16.7%) patients with UC and one of the two patients with indeterminate colitis had serum macro-creatinkinase type 1 while no CD patients displayed this macromolecule (P < 0,001). Sensitivity, specificity, positive and negative predictive value, and positive and negative likelihood ratio were calculated for ulcerative colitis versus Crohn’s disease diagnosis, being 16.7, 98.9, 92.3, 59, 14.5, and 0.84% respectively. There was no correlation with age, gender, time from diagnosis, associated diseases, concomitant medication or disease activity. In conclusion our data suggests that the presence of macro-CK in IBD favors the diagnosis of ulcerative colitis. Further studies are necessary to understand the significance of this finding in a subset of patients with IBD.
Literature
1.
go back to reference Lang H, Wurzburg U (1982) Creatine kinase, an enzyme of many forms. Clin Chem 28(7):1439–1447PubMed Lang H, Wurzburg U (1982) Creatine kinase, an enzyme of many forms. Clin Chem 28(7):1439–1447PubMed
2.
go back to reference Mifflin TE, Bruns DE, Wrotnoski U, MacMillan RH, Stallings RG, Felder RA, Herold DA (1985) University of Virginia case conference. Macroamylase, macro creatine kinase, and other macroenzymes. Clin Chem 31(10):1743–1748PubMed Mifflin TE, Bruns DE, Wrotnoski U, MacMillan RH, Stallings RG, Felder RA, Herold DA (1985) University of Virginia case conference. Macroamylase, macro creatine kinase, and other macroenzymes. Clin Chem 31(10):1743–1748PubMed
3.
go back to reference Laureys M, Sion JP, Slabbynck H, Steenssens L, Cobbaert C, Derde MP, Gorus FK (1991) Macromolecular creatine kinase type 1: a serum marker associated with disease. Clin Chem 37(3):430–434PubMed Laureys M, Sion JP, Slabbynck H, Steenssens L, Cobbaert C, Derde MP, Gorus FK (1991) Macromolecular creatine kinase type 1: a serum marker associated with disease. Clin Chem 37(3):430–434PubMed
4.
go back to reference Lee KN, Csako G, Bernhardt P, Elin RJ (1994) Relevance of macro creatine kinase type 1 and type 2 isoenzymes to laboratory and clinical data. Clin Chem 40(7 Pt 1):1278–1283PubMed Lee KN, Csako G, Bernhardt P, Elin RJ (1994) Relevance of macro creatine kinase type 1 and type 2 isoenzymes to laboratory and clinical data. Clin Chem 40(7 Pt 1):1278–1283PubMed
5.
go back to reference Stein W, Bohner J, Renn W, Maulbetsch R (1985) Macro creatine kinase type 2: results of a prospective study in hospitalized patients. Clin Chem 31(12):1959–1964PubMed Stein W, Bohner J, Renn W, Maulbetsch R (1985) Macro creatine kinase type 2: results of a prospective study in hospitalized patients. Clin Chem 31(12):1959–1964PubMed
6.
go back to reference Remaley AT, Wilding P (1989) Macroenzymes: biochemical characterization, clinical significance, and laboratory detection. Clin Chem 35(12):2261–2270PubMed Remaley AT, Wilding P (1989) Macroenzymes: biochemical characterization, clinical significance, and laboratory detection. Clin Chem 35(12):2261–2270PubMed
7.
go back to reference Tozawa T (1989) Enzyme-linked immunoglobulins and their clinical significance. Electrophoresis 10(8–9):640–644PubMedCrossRef Tozawa T (1989) Enzyme-linked immunoglobulins and their clinical significance. Electrophoresis 10(8–9):640–644PubMedCrossRef
8.
go back to reference Perez Calle JL, Marcos IM, Carneros JA, Barrio J, Trascasa C, Munoz E, Mancheno E, Gonzalez Lara V (2001) [Macromolecular creatinine kinase in patients diagnosed with ulcerative colitis]. Gastroenterol Hepatol 24(1):16–19PubMed Perez Calle JL, Marcos IM, Carneros JA, Barrio J, Trascasa C, Munoz E, Mancheno E, Gonzalez Lara V (2001) [Macromolecular creatinine kinase in patients diagnosed with ulcerative colitis]. Gastroenterol Hepatol 24(1):16–19PubMed
9.
go back to reference Szasz G, Gerhardt W, Gruber W, Bernt E (1976) Creatine kinase in serum: 2. Interference of adenylate kinase with the assay. Clin Chem 22(11):1806–1811PubMed Szasz G, Gerhardt W, Gruber W, Bernt E (1976) Creatine kinase in serum: 2. Interference of adenylate kinase with the assay. Clin Chem 22(11):1806–1811PubMed
10.
go back to reference Szasz G, Gruber W, Bernt E (1976) Creatine kinase in serum: 1. Determination of optimum reaction conditions. Clin Chem 22(5):650–656PubMed Szasz G, Gruber W, Bernt E (1976) Creatine kinase in serum: 1. Determination of optimum reaction conditions. Clin Chem 22(5):650–656PubMed
11.
go back to reference Wurzburg U, Hennrich N, Lang H, Prellwitz W, Neumeier D, Knedel M (1976) [Determination of creatine kinase-MB in serum using inhibiting antibodies (author’s transl)]. Klin Wochenschr 54(8):357–360PubMedCrossRef Wurzburg U, Hennrich N, Lang H, Prellwitz W, Neumeier D, Knedel M (1976) [Determination of creatine kinase-MB in serum using inhibiting antibodies (author’s transl)]. Klin Wochenschr 54(8):357–360PubMedCrossRef
12.
go back to reference Rosa-Jimenez F, Gasso de Campos M, Camacho Reina MV, Vazquez de Castroviejo E, Hernandez Burruezo JJ, Pousibet Sanfeliu H (1997) [Macro creatine kinase type 1 as a cause of increase of CF-MB isoenzyme. Apropos of 7 cases]. Rev Esp Cardiol 50(3):166–172PubMed Rosa-Jimenez F, Gasso de Campos M, Camacho Reina MV, Vazquez de Castroviejo E, Hernandez Burruezo JJ, Pousibet Sanfeliu H (1997) [Macro creatine kinase type 1 as a cause of increase of CF-MB isoenzyme. Apropos of 7 cases]. Rev Esp Cardiol 50(3):166–172PubMed
13.
go back to reference Stein W, Bohner J (1985) Need the small laboratory still use the plasma creatine kinase/aspartate aminotransferase ratio? Clin Chem 31(11):1910PubMed Stein W, Bohner J (1985) Need the small laboratory still use the plasma creatine kinase/aspartate aminotransferase ratio? Clin Chem 31(11):1910PubMed
14.
go back to reference Keren DF, Goeken JA (1997) Autoimmune reactivity in inflammatory bowel disease. Clin Lab Med 7(3):465–481 Keren DF, Goeken JA (1997) Autoimmune reactivity in inflammatory bowel disease. Clin Lab Med 7(3):465–481
15.
go back to reference Gisbert JP, Gomollon F, Mate J, Pajares JM (2003) [The role of anti-neutrophil cytoplasmic antibodies (ANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA) in inflammatory bowel disease]. Gastroenterol Hepatol 26(5):312–324PubMedCrossRef Gisbert JP, Gomollon F, Mate J, Pajares JM (2003) [The role of anti-neutrophil cytoplasmic antibodies (ANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA) in inflammatory bowel disease]. Gastroenterol Hepatol 26(5):312–324PubMedCrossRef
Metadata
Title
Prevalence of Macrocreatinkinase Type 1 in Patients with Inflammatory Bowel Disease
Authors
J. L. Perez-Calle
I. Marin-Jimenez
P. Lopez-Serrano
J. P. Gisbert
A. S. Pena
C. Fernandez-Rodriguez
Publication date
01-02-2008
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 2/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-9888-z

Other articles of this Issue 2/2008

Digestive Diseases and Sciences 2/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.